Harvard Bioscience Inc. (HBIO) Trading Down 2.5%
Harvard Bioscience Inc. (NASDAQ:HBIO) was down 2.5% on Tuesday . The company traded as low as $2.67 and last traded at $2.72, with a volume of 70,205 shares changing hands. The stock had previously closed at $2.79.
Separately, Zacks Investment Research upgraded Harvard Bioscience from a “sell” rating to a “hold” rating in a report on Tuesday, July 12th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/harvard-bioscience-inc-hbio-trading-down-2-5.html
The stock has a 50 day moving average of $2.78 and a 200-day moving average of $2.98. The company’s market cap is $91.62 million.
Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. The company had revenue of $26.10 million for the quarter, compared to analyst estimates of $26.60 million. Analysts expect that Harvard Bioscience Inc. will post $0.16 earnings per share for the current year.
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.
Receive News & Ratings for Harvard Bioscience Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.